|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Aerie Pharmaceuticals insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Aerie Pharmaceuticals insider buys are important for investors to follow.
Date | Insider | Price | Amount |
9-9-2019 Insider Buy |
Richard J. Rubino Chief Financial Officer |
$19.93
CAGR »
|
$100,447.20 5,040 shares |
9-9-2019 Insider Buy |
Vicente Anido Jr. Chief Executive Officer |
$19.01
CAGR »
|
$498,952.50 26,250 shares |
9-5-2019 Insider Buy |
Foresite Capital Management II, LLC >10% Owner |
$18.47
CAGR »
|
$2,140,890.00 115,900 shares |
9-3-2019 Insider Buy |
Foresite Capital Management II, LLC >10% Owner |
$21.00
CAGR »
|
$1,574,741.00 75,000 shares |
8-23-2019 Insider Buy |
Foresite Capital Management II, LLC >10% Owner |
$23.45
CAGR »
|
$1,082,449.25 46,153 shares |
8-20-2019 Insider Buy |
Foresite Capital Management II, LLC >10% Owner |
$23.88
CAGR »
|
$3,673,288.98 153,847 shares |
8-14-2019 Insider Buy |
Foresite Capital Management II, LLC >10% Owner |
$24.73
CAGR »
|
$13,341,170.45 539,555 shares |
11-16-2018 Insider Buy |
Gerald D. Cagle Director |
$41.75
CAGR »
|
$83,493.20 2,000 shares |
5-25-2018 Insider Buy |
Gerald D. Cagle Director |
$49.45
CAGR »
|
$49,450.00 1,000 shares |
5-21-2018 Insider Buy |
Gerald D. Cagle Director |
$50.24
CAGR »
|
$50,245.00 1,000 shares |
5-9-2017 Insider Buy |
Gerald D. Cagle Director |
$39.90
CAGR »
|
$39,900.00 1,000 shares |
4-19-2017 Insider Buy |
Gerald D. Cagle Director |
$41.70
CAGR »
|
$83,400.00 2,000 shares |
8-28-2015 Insider Buy |
Gerald D. Cagle Director |
$18.24
CAGR »
|
$84,765.64 4,646 shares |
10-25-2013 Insider Buy |
Clarus Lifesciences II, L.P. >10% Owner |
$10.00
CAGR »
|
$3,210,000.00 321,000 shares |
5-16-2014 Insider Buy |
Gerald D. Cagle Director |
$15.07
CAGR »
|
$27,939.78 1,854 shares |
10-30-2013 Insider Buy |
ACP IV, L.P. >10% Owner |
$10.00
CAGR »
|
$1,100,000.00 110,000 shares |
10-30-2013 Insider Buy |
Richard J. Rubino Chief Financial Officer |
$10.00
CAGR »
|
$100,000.00 10,000 shares |
10-30-2013 Insider Buy |
Vicente Anido Jr. Chief Executive Officer |
$10.00
CAGR »
|
$280,000.00 28,000 shares |
10-30-2013 Insider Buy |
Thomas A. Mitro President and COO |
$10.00
CAGR »
|
$50,000.00 5,000 shares |
10-30-2013 Insider Buy |
Brian Levy Chief Medical Officer |
$10.00
CAGR »
|
$60,000.00 6,000 shares |
10-25-2013 Insider Buy |
Anand Mehra Director and >10% Owner |
$10.00
CAGR »
|
$2,850,000.00 285,000 shares |
Also See: Institutional Holders of AERI
Also See: SEC filings
Below we present the annualized performance delivered by Aerie Pharmaceuticals stock since 9-9-2019 (the date of the most recent
insider purchase). The performance of the investment from the time Aerie Pharmaceuticals insider buying occurred is the ultimate
test of whether insiders were right about AERI being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/10/2019 |
|
End date: |
11/21/2022 |
|
Start price/share: |
$22.16 |
|
End price/share: |
$15.25 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-31.18% |
|
Average Annual Total Return: |
-11.02% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,882.33 |
|
Years: |
3.20 |
|
Aerie Pharmaceuticals Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Aerie Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding AERI
|
|